<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03234985</url>
  </required_header>
  <id_info>
    <org_study_id>69HCL17_0351</org_study_id>
    <nct_id>NCT03234985</nct_id>
  </id_info>
  <brief_title>Study of Intracellular Nucleotide Pools Determination as Biomarker of the Efficacy of the Induction Treatment in Acute Myeloid Leukemia</brief_title>
  <acronym>NUCLARA</acronym>
  <official_title>Study of Intracellular Nucleotide Pools Determination as Biomarker of the Efficacy of the Induction Treatment in Acute Myeloid Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospices Civils de Lyon</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Treatment of acute myeloid leukemia (AML) consists in two main phases: induction and
      consolidation. Standard chemotherapy combination for induction treatment associates
      cytarabine (AraC), a nucleoside analog, and an anthracycline (most often daunorubucin). About
      60-70% of patients achieved complete remission after this standard chemotherapy. As
      cytarabine competes with endogenous nucleotides to exert its activity, the aim of this
      protocol is to study in vivo the effect of intracellular nucleotide pools on the efficacy of
      the induction treatment. Thus, intracellular nucleotides levels will be determined in
      peripheral blood mononuclear cells of patients with acute myeloid leukemia before treatment,
      and results will be compared with the efficacy of the treatment. This parameter will be
      assessed by the achievement of complete remission.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2017</start_date>
  <completion_date type="Anticipated">February 2019</completion_date>
  <primary_completion_date type="Anticipated">February 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Complete remission</measure>
    <time_frame>30 days</time_frame>
    <description>Primary endpoint will be the achievement of complete remission after induction treatment and bone marrow aplasia.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">44</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>acute myeloid leukemia patients</arm_group_label>
    <description>Patients over 18 years with acute myeloid leukemia</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Biological analyses</intervention_name>
    <description>Biological analyses will be realized on samples collected before induction treatment and at the end of bone marrow aplasia i.e. about day 30 to determine the nucleotide pools in peripheral blood mononuclear cells.</description>
    <arm_group_label>acute myeloid leukemia patients</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients over 18 years with acute myeloid leukemia (except acute myeloid leukemia3)
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age over 18 years

          -  acute myeloid leukemia

          -  standard induction chemotherapy with cytarabine and daunorubicin

          -  patients who received the information and did not object to participate to the study

        Exclusion Criteria:

        - patients with acute myeloid leukemia 3
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Xavier THOMAS, MD</last_name>
    <phone>04 78 86 22 40</phone>
    <phone_ext>+33</phone_ext>
    <email>xavier.thomas@chu-lyon.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Christelle MACHON, PharmD</last_name>
    <phone>04 72 66 64 00</phone>
    <phone_ext>+33</phone_ext>
    <email>christelle.machon@chu-lyon.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Service d'hématologie - Centre Hospitalier Lyon Sud - Hospices Civils de LYON</name>
      <address>
        <city>Pierre-Bénite</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xavier THOMAS, MD</last_name>
      <phone>04 78 86 22 40</phone>
      <phone_ext>+33</phone_ext>
      <email>xavier.thomas@chu-lyon.fr</email>
    </contact>
    <contact_backup>
      <last_name>Christelle MACHON, PharmD</last_name>
      <phone>04 72 66 64 00</phone>
      <phone_ext>+33</phone_ext>
      <email>christelle.machon@chu-lyon.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Xavier THOMAS, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 27, 2017</study_first_submitted>
  <study_first_submitted_qc>July 27, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 1, 2017</study_first_posted>
  <last_update_submitted>July 27, 2017</last_update_submitted>
  <last_update_submitted_qc>July 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 1, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

